Protocols

AstraZeneca auctions off more assets in $766M deal, reports positive data for Farxiga

AstraZeneca CEO Pascal Soriot has sold off another set of assets. The pharma giant is selling a portfolio of anesthetics to Aspen Global for $555 million in cash and $211 million in milestones. AstraZeneca has been steadily auctioning off a variety of assets as it focuses more and more on its new cancer franchise.

AstraZeneca has rolled out new data from a late-stage study that highlights how Farxiga, approved for Type 2 diabetes, also helps Type 1 patients. That’s a much smaller market, but an opening here could expand franchise sales. The drug is an SGLT-2 inhibitor with several rivals on the market.

Recipharm and the CRO Clinical Trial Consultants have partnered on a new service designed to provide a streamlined approach to gaining proof-of-concept data.



The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing